United States Inactivated Vaccine Market Report 2017

December 2017 | 99 pages | ID: UC2E731458FEN
QYResearch

Abstracts

In this report, the United States Inactivated Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Inactivated Vaccine in these regions, from 2012 to 2022 (forecast).

United States Inactivated Vaccine market competition by top manufacturers/players, with Inactivated Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Astellas Pharma (Japan)
• CSL Limited (Australia)
• Emergent BioSolutions (U.S.)
• GlaxoSmithKline (U.K.)
• Johnson & Johnson (U.S.)
• MedImmune (U.S.)
• Merck & Co (U.S.)
• Pfizer (U.S.)
• Sanofi Pasteur (France)
• Serum Institute of India Pvt (India)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• By End User
• Pediatrics
• Adults
• By Disease Indication
• Pneumococcal
• Influenza
• HPV
• Hepatitis
• Rotavirus
• DTP
• Polio
• MMR

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Medical Center
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Inactivated Vaccine Market Report 2017

1 INACTIVATED VACCINE OVERVIEW

1.1 Product Overview and Scope of Inactivated Vaccine
1.2 Classification of Inactivated Vaccine by Product Category
  1.2.1 United States Inactivated Vaccine Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Inactivated Vaccine Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Pediatrics
  1.2.4 Adults
1.3 United States Inactivated Vaccine Market by Application/End Users
  1.3.1 United States Inactivated Vaccine Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital
  1.3.3 Medical Center
  1.3.4 Others
1.4 United States Inactivated Vaccine Market by Region
  1.4.1 United States Inactivated Vaccine Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Inactivated Vaccine Status and Prospect (2012-2022)
  1.4.3 Southwest Inactivated Vaccine Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Inactivated Vaccine Status and Prospect (2012-2022)
  1.4.5 New England Inactivated Vaccine Status and Prospect (2012-2022)
  1.4.6 The South Inactivated Vaccine Status and Prospect (2012-2022)
  1.4.7 The Midwest Inactivated Vaccine Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Inactivated Vaccine (2012-2022)
  1.5.1 United States Inactivated Vaccine Sales and Growth Rate (2012-2022)
  1.5.2 United States Inactivated Vaccine Revenue and Growth Rate (2012-2022)

2 UNITED STATES INACTIVATED VACCINE MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Inactivated Vaccine Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Inactivated Vaccine Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Inactivated Vaccine Average Price by Players/Suppliers (2012-2017)
2.4 United States Inactivated Vaccine Market Competitive Situation and Trends
  2.4.1 United States Inactivated Vaccine Market Concentration Rate
  2.4.2 United States Inactivated Vaccine Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Inactivated Vaccine Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES INACTIVATED VACCINE SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Inactivated Vaccine Sales and Market Share by Region (2012-2017)
3.2 United States Inactivated Vaccine Revenue and Market Share by Region (2012-2017)
3.3 United States Inactivated Vaccine Price by Region (2012-2017)

4 UNITED STATES INACTIVATED VACCINE SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Inactivated Vaccine Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Inactivated Vaccine Revenue and Market Share by Type (2012-2017)
4.3 United States Inactivated Vaccine Price by Type (2012-2017)
4.4 United States Inactivated Vaccine Sales Growth Rate by Type (2012-2017)

5 UNITED STATES INACTIVATED VACCINE SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Inactivated Vaccine Sales and Market Share by Application (2012-2017)
5.2 United States Inactivated Vaccine Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES INACTIVATED VACCINE PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Astellas Pharma (Japan)
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Inactivated Vaccine Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Astellas Pharma (Japan) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 CSL Limited (Australia)
  6.2.2 Inactivated Vaccine Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 CSL Limited (Australia) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Emergent BioSolutions (U.S.)
  6.3.2 Inactivated Vaccine Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 GlaxoSmithKline (U.K.)
  6.4.2 Inactivated Vaccine Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Johnson & Johnson (U.S.)
  6.5.2 Inactivated Vaccine Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Johnson & Johnson (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 MedImmune (U.S.)
  6.6.2 Inactivated Vaccine Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 MedImmune (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Merck & Co (U.S.)
  6.7.2 Inactivated Vaccine Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Merck & Co (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Pfizer (U.S.)
  6.8.2 Inactivated Vaccine Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Pfizer (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Sanofi Pasteur (France)
  6.9.2 Inactivated Vaccine Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Sanofi Pasteur (France) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Serum Institute of India Pvt (India)
  6.10.2 Inactivated Vaccine Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 INACTIVATED VACCINE MANUFACTURING COST ANALYSIS

7.1 Inactivated Vaccine Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Inactivated Vaccine

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Inactivated Vaccine Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Inactivated Vaccine Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES INACTIVATED VACCINE MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Inactivated Vaccine Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Inactivated Vaccine Sales Volume Forecast by Type (2017-2022)
11.3 United States Inactivated Vaccine Sales Volume Forecast by Application (2017-2022)
11.4 United States Inactivated Vaccine Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Inactivated Vaccine
Figure United States Inactivated Vaccine Market Size (K MT) by Type (2012-2022)
Figure United States Inactivated Vaccine Sales Volume Market Share by Type (Product Category) in 2016
Figure Pediatrics Product Picture
Figure Adults Product Picture
Figure United States Inactivated Vaccine Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Inactivated Vaccine by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Inactivated Vaccine Market Size (Million USD) by Region (2012-2022)
Figure The West Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2022)
Figure United States Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Inactivated Vaccine Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Inactivated Vaccine Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Inactivated Vaccine Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Inactivated Vaccine Sales Share by Players/Suppliers
Figure 2017 United States Inactivated Vaccine Sales Share by Players/Suppliers
Figure United States Inactivated Vaccine Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Inactivated Vaccine Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Inactivated Vaccine Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Inactivated Vaccine Revenue Share by Players/Suppliers
Figure 2017 United States Inactivated Vaccine Revenue Share by Players/Suppliers
Table United States Market Inactivated Vaccine Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Inactivated Vaccine Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Inactivated Vaccine Market Share of Top 3 Players/Suppliers
Figure United States Inactivated Vaccine Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Inactivated Vaccine Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Inactivated Vaccine Product Category
Table United States Inactivated Vaccine Sales (K MT) by Region (2012-2017)
Table United States Inactivated Vaccine Sales Share by Region (2012-2017)
Figure United States Inactivated Vaccine Sales Share by Region (2012-2017)
Figure United States Inactivated Vaccine Sales Market Share by Region in 2016
Table United States Inactivated Vaccine Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Inactivated Vaccine Revenue Share by Region (2012-2017)
Figure United States Inactivated Vaccine Revenue Market Share by Region (2012-2017)
Figure United States Inactivated Vaccine Revenue Market Share by Region in 2016
Table United States Inactivated Vaccine Price (USD/MT) by Region (2012-2017)
Table United States Inactivated Vaccine Sales (K MT) by Type (2012-2017)
Table United States Inactivated Vaccine Sales Share by Type (2012-2017)
Figure United States Inactivated Vaccine Sales Share by Type (2012-2017)
Figure United States Inactivated Vaccine Sales Market Share by Type in 2016
Table United States Inactivated Vaccine Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Inactivated Vaccine Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Inactivated Vaccine by Type (2012-2017)
Figure Revenue Market Share of Inactivated Vaccine by Type in 2016
Table United States Inactivated Vaccine Price (USD/MT) by Types (2012-2017)
Figure United States Inactivated Vaccine Sales Growth Rate by Type (2012-2017)
Table United States Inactivated Vaccine Sales (K MT) by Application (2012-2017)
Table United States Inactivated Vaccine Sales Market Share by Application (2012-2017)
Figure United States Inactivated Vaccine Sales Market Share by Application (2012-2017)
Figure United States Inactivated Vaccine Sales Market Share by Application in 2016
Table United States Inactivated Vaccine Sales Growth Rate by Application (2012-2017)
Figure United States Inactivated Vaccine Sales Growth Rate by Application (2012-2017)
Table Astellas Pharma (Japan) Basic Information List
Table Astellas Pharma (Japan) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table CSL Limited (Australia) Basic Information List
Table CSL Limited (Australia) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Emergent BioSolutions (U.S.) Basic Information List
Table Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline (U.K.) Basic Information List
Table GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson (U.S.) Basic Information List
Table Johnson & Johnson (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Johnson & Johnson (U.S.) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Johnson & Johnson (U.S.) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson (U.S.) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table MedImmune (U.S.) Basic Information List
Table MedImmune (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure MedImmune (U.S.) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure MedImmune (U.S.) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure MedImmune (U.S.) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Merck & Co (U.S.) Basic Information List
Table Merck & Co (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Merck & Co (U.S.) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Merck & Co (U.S.) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Merck & Co (U.S.) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Pfizer (U.S.) Basic Information List
Table Pfizer (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Pfizer (U.S.) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Pfizer (U.S.) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Pfizer (U.S.) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Sanofi Pasteur (France) Basic Information List
Table Sanofi Pasteur (France) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Sanofi Pasteur (France) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Sanofi Pasteur (France) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Sanofi Pasteur (France) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Serum Institute of India Pvt (India) Basic Information List
Table Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Serum Institute of India Pvt (India) Inactivated Vaccine Sales Growth Rate (2012-2017)
Figure Serum Institute of India Pvt (India) Inactivated Vaccine Sales Market Share in United States (2012-2017)
Figure Serum Institute of India Pvt (India) Inactivated Vaccine Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Inactivated Vaccine
Figure Manufacturing Process Analysis of Inactivated Vaccine
Figure Inactivated Vaccine Industrial Chain Analysis
Table Raw Materials Sources of Inactivated Vaccine Major Players/Suppliers in 2016
Table Major Buyers of Inactivated Vaccine
Table Distributors/Traders List
Figure United States Inactivated Vaccine Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Inactivated Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Inactivated Vaccine Price (USD/MT) Trend Forecast (2017-2022)
Table United States Inactivated Vaccine Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Inactivated Vaccine Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Inactivated Vaccine Sales Volume (K MT) Forecast by Type in 2022
Table United States Inactivated Vaccine Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Inactivated Vaccine Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Inactivated Vaccine Sales Volume (K MT) Forecast by Application in 2022
Table United States Inactivated Vaccine Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Inactivated Vaccine Sales Volume Share Forecast by Region (2017-2022)
Figure United States Inactivated Vaccine Sales Volume Share Forecast by Region (2017-2022)
Figure United States Inactivated Vaccine Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources